Shares of Editas Medicine Inc. rallied 9.3% in premarket trading on Tuesday after the company said in a news release that it had positive results from the first two patients enrolled in a Phase 1/2 clinical trial assessing its experimental treatment for sickle-cell disease. Editas said the therapy was well-tolerated. “These promising clinical results from the RUBY trial suggest clinical proof of concept for EDIT-301 and support our belief that EDIT-301 can be a clinically differentiated, one-time, durable medicine that can provide life changing clinical benefits to patients with severe sickle cell disease long term,” Dr. Baisong Mei, chief medical officer for Editas, said in a news release. The company’s stock has declined 62.9% this year as the S&P 500 is down about 16%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.